Treating respiratory diseases, e.g. bronchitis or asthma, using combination of reversible proton pump inhibitor, e.g. AU-461, and conventional respiratory therapeutic agent, e.g. cilomilast
WO02066430A1
Tryptase inhibitors
AU3844902A
Process for the production and purification of proteins and the production of arrays of proteins
AU2193902A
Rapidly disintegrating tablet comprising an acid-labile active ingredient
AU2483502A
Dihydroisoquinolines as novel phosphodiesterase inhibitors
AU2632502A
Process for the rehydration of magaldrate powder
WO0234749A1
Polysubstituted imidazopyridines as gastric secretion inhibitors
WO0205616A1
Novel 6-phenylphenanthridines
AU6758901A
Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
WO0206239A1
Phenanthridine n-oxides
ZA200102107B
Tetrahydropyridoethers.
AU3375701A
Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
CA2392127A1
Tryptase inhibitors
CA2392121A1
Tryptase inhibitors
DE10061138C1
Pharmaceutical preparation in the form of a juice containing an acid-labile active ingredient
DE10061135C1
Stable gel preparation for oral administration of acid-labile drug, especially proton pump inhibitor, comprises multiple drug units dispersed in gel base
DE10061136C1
Stable, rapidly disintegrating tablets containing proton pump inhibitors, useful for treating elevated gastric secretion, comprising multiple drug units and auxiliaries including basic filler
WO0139573A2
Novel use of lung surfactant for treating legionnaire's disease
DE10055815A1
Identifying and quantifying hydrophobic proteins, useful e.g. for analysis of impurities in recombinant surfactant protein, by depositing on hydrophobic membrane before immunoassay
DE10055820C1
Preparation of 16,17-cyclohexylmethylene-dioxy-pregnadiene derivative, useful as glucocorticoid, by reacting 16,17-ketal with cyclohexylaldehyde to give high epimeric purity
